The significant number of active agents against the FLT3-ITD positive AML line MV4;11, reflects the number of kinase inhibitors that possess FLT3 inhibitory activity either by design (e.g. AC220, tandutinib) or the known propensity of many kinase inhibitors to bind to FLT3 with high affinity [18]. The gene discussed is FLT3; the disease is acute myeloid leukemia.